The key role of insulin resistance in the cardiometabolic syndrome

American Journal of the Medical Sciences

Volumn 330, Issue 6, 2005, Pages 290-294

  Gill, Harvinder ^a   Mugo, Maryann ^a   Whaley Connell, Adam ^a   Stump, Craig ^a   Sowers, James R ^a  

^a University of Missouri   (United States)

Author keywords

Adipocytokines; Cardiometabolic syndrome; Control obesity; Genetics; Hyperinsulinemia; Insulin resistance

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; ADIPOCYTOKINE; ADIPONECTIN; C REACTIVE PROTEIN; FATTY ACID; FIBRINOGEN; INSULIN; INTERLEUKIN 6; LEPTIN; PLASMINOGEN ACTIVATOR INHIBITOR 1;

ACCURACY; CARDIOVASCULAR DISEASE; CONFERENCE PAPER; DISEASE ASSOCIATION; DYSLIPIDEMIA; ENVIRONMENTAL FACTOR; HEREDITY; HUMAN; HYPERGLYCEMIA; HYPERINSULINEMIA; HYPERTENSION; IMPAIRED GLUCOSE TOLERANCE; INSULIN RESISTANCE; INSULIN SENSITIVITY; LIPODYSTROPHY; METABOLIC SYNDROME X; MISSENSE MUTATION; MOLECULAR INTERACTION; MOLECULAR MECHANICS; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PATHOGENESIS; PATIENT CARE; SIGNAL TRANSDUCTION; SINGLE NUCLEOTIDE POLYMORPHISM; TARGET ORGAN;

EID: 29244436880     PISSN: 00029629     EISSN: None     Source Type: Journal    
DOI: 10.1097/00000441-200512000-00006     Document Type: Conference Paper

References (41)

1. Reaven G. Banting Lecture. Role of insulin resistance in human disease. Diabetes 1988;37:1595-1607.
2. McFarlane SI, Banerji M, Sowers JR. Insulin resistance and cardiovascular disease. J Clin Endocrinol Metab 2001; 86:713-8.
3. Ford ES, Giles WH, Mokdad AH. Increasing prevalence of the metabolic syndrome among U.S. Adults. Diabetes Care 2004;27:2444-9.
4. Third Report on the National Cholesterol Education Program Expert Panel on the Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (ATP III). NIH Publication No. 01-3670, 2001.
5. Sowers JR. Obesity as a cardiovascular risk factor. Am J Med 2003;115:37S-41S.
6. Sowers JR, Sowers PS, Peuler JD. Role of insulin resistance and hyperinsulinemia in development of hypertension and atherosclerosis. J Lab Clin Med 1994;123:647-52.
7. Hunter SJ, Garvey T. Insulin action and insulin resistance: diseases involving defects in insulin receptors, signal transduction and glucose transport effector system. Am J Med 1998;5:331-46.
8. Sowers JR. Insulin and Insulin-like growth factor in normal and pathological cardiovascular physiology. Hypertension 1997;29:691-9.
9. Sowers JR. Insulin resistance and hypertension. Am J Physiol Circ Physiol 2004;286:H1597-602.
10. Wang CC, Goalstone ML, Draznin B. Molecular mechanisms of insulin resistance that impact cardiovascular biology. Diabetes 2004;53:2735-40.
11. Morrill AC, Chinn CD. The obesity epidemic in the United States. J Public Health Policy. 2004;25:353-366.
12. Pittas AG, Joseph NA, Greenberg AS. Adipocytokines and insulin resistance. J Clin Endocrinol Metab 2004;89:447-52.
13. Schrauwen P, Hesselink MK. Oxidative capacity, lipotoxicity, and mitochondrial damage in type 2 diabetes. Diabetes 2004;53:1412-7.
14. Boden G, Shulman GI. Free fatty acids in obesity and type 2 diabetes: defining their role in the development of insulin resistance and beta-cell dysfunction. Eur J Clin Invest. 2002;32:14-23.
15. Lelliott C, Vidal-Puig AJ. Lipotoxicity, an imbalance between lipogenesis de novo and fatty acid oxidation. Int J Obes Relat Metab Disord 2004;28 Suppl 4:S22-8.
16. Yang WS, Lee WJ, Funahashi T, et al. Weight reduction increases plasma levels of an adipose derived anti-inflammatory protein, adiponectin. J Clin Endocrinol Metab 2001;86:3815-9.
17. Weyer C, Funahashi T, Tanaka S, et al. Hypoadiponectinemia in obesity and type 2 diabetes: close association with insulin resistance and hyperinsulinemia. J Clin Endocrinol Metab 2001;86:1930-5.
18. Pelleymounter MA, Cullen MJ, Baker MB, et al. Effects of the obese gene product on body weight regulation in ob/ob mice. Science 1995;269:540-3.
19. Considine RV, Sinha MK, Heiman ML, et al. Serum immunoreactive-leptin concentrations in normal weight and obese humans. N Engl J Med 1996;334:292-5.
20. Laakso M. Gene variants, insulin resistance and dyslipidemia. Curr Opin Lipidol 2004;15:115-20.
21. Frittitta L, Barrata R, Spampinato D. The Q121K PC-1 variant and obesity have additive and independent effects in causing insulin resistance. J Clin Endocrinol Metab 2001;86:5888-91.
22. Baroni MG, Arca M, Sentinelli F. The G972R variant of the insulin receptor substrate-1 (IRS-1) gene, body fat distribution and insulin resistance. Diabetologia 2001;44:367-72.
23. Almind K, Inoue G, Pedersen O, et al. A common amino-acid polymorphism in insulin receptor substrate-1 causes impaired insulin signalling. Evidence from transfection studies. J Clin Invest 1996;97:2569-75.
24. Gurnell M, Savage DB, Chatterjee VK, et al. The metabolic syndrome: peroxisome proliferator-activated receptor gamma and its therapeutic modulation. J Clin Endocrinol Metab 2003;88:2412-21.
25. Savage DB, Tan GD, Acerini CL, et al. Human metabolic syndrome resulting from dominant-negative mutations in the nuclear receptor peroxisome proliferator-activated receptor-gamma. Diabetes 2003;52:910-7.
26. Deeb SS, Fajas L, Nemoto M, et al. A Pro121Ala substitution in PPAR-gamma 2 associated with decreased receptor activity, lower body mass index and improved insulin sensitivity. Nat Genet 1998;20:284-7.
27. Kadowaki T, Hara K, Yamauchi T, et al. Molecular mechanims of insulin resistance in obesity. Exp Biol Med 2003;228:1111-7.
28. Sowers JR, Frohlich ED. Insulin and insulin resistance: impact on blood pressure and cardiovascular disease. Med Clin North Am 2004;88:63-82.
29. Epstein M, Sowers JR. Diabetes mellitus and hypertension. Hypertension 1992;19:403-18.
30. Lind L, Berne C, Lithell H. Prevalence of insulin resistance in essential hypertension. J Hypertens 1995;13:1457-62.
31. Marigliano A, Tedde R, Sechi LA, et al. Insulinemia and blood pressure: relationships in patients with primary and secondary hypertension, and with or without glucose metabolism impairment. Am J Hypertens 1990;3:521-6.
32. Facchini FS, Chen YD, Clinkingbeard C. Insulin resistance, hyperinsulinemia and dyslipidemia in non-obese individuals with a family history of hypertension. Am J Hypertens 1992;5:694-9.
33. Denker PS, Pollock VE. Fasting serum insulin levels in essential hypertension: a meta-analysis. Arch Intern Med 1992;152:1649-51.
34. Sawicki PT, Heinemann L, Starke A. Hyperinsulinemia in not linked with blood pressure elevation in patients with insulinoma. Diabetologia 1992;35:649-52.
35. Heise T, Magnusson K, Heinemann L. Insulin resistance and the effect of insulin on blood pressure in essential hypertension. Hypertension 1998;32:243-8.
36. Edelson GW, Sowers JR. Insulin resistance in hypertension: a focused review. Am J Med Sci 1993;306:345-7.
37. Duncan BB, Schmidt MI, Pankow JS. Low-grade systemic inflammation and the development of type 2 diabetes mellitus: the atherosclerosis risk in communities study. Diabetes 2003;52:1799-805.
38. Weisberg SP, McCann D, Desai M. Obesity is associated with macrophage accumulation in adipose tissue. J Clin Invest 2003;112:1796-808.
39. DeFronzo RA, Ferrannini E. Insulin resistance: a multifaceted syndrome responsible for NIDDM, obesity, hypertension, dyslipidemia and atherosclerotic cardiovascular disease. Diabetes Care 1991;14:173-94.
40. Sowers JR, Haffner S. Treatment of cardiovascular and renal risk factors in the diabetic hypertensive. Hypertension 2002;40:781-8.
41. Dzau VJ. Theodore Cooper Lecture: Tissue angiotensin and pathobiology of vascular disease: a unifying hypothesis. Hypertension 2001;37:1047-52.